The stock of Novo Nordisk A S (ADR) (NYSE:NVO) hit a new 52-week low and has $37.01 target or 9.00% below today’s $40.67 share price. The 5 months bearish chart indicates high risk for the $81.15 billion company. The 1-year low was reported on Oct, 10 by Barchart.com. If the $37.01 price target is reached, the company will be worth $7.30 billion less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 1.93 million shares traded hands. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 28.83% since March 7, 2016 and is downtrending. It has underperformed by 36.42% the S&P500.
Analysts await Novo Nordisk A S (ADR) (NYSE:NVO) to report earnings on November, 3. They expect $0.56 earnings per share, up 14.29% or $0.07 from last year’s $0.49 per share. NVO’s profit will be $1.12B for 18.16 P/E if the $0.56 EPS becomes a reality. After $0.60 actual earnings per share reported by Novo Nordisk A S (ADR) for the previous quarter, Wall Street now forecasts -6.67% negative EPS growth.
Novo Nordisk A S (ADR) (NYSE:NVO) Ratings Coverage
Out of 10 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 3 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 30% are positive. Novo Nordisk (ADR) has been the topic of 10 analyst reports since August 28, 2015 according to StockzIntelligence Inc. Goldman Sachs upgraded the stock to “Conviction Buy” rating in Monday, February 15 report. The firm has “Equal-Weight” rating by Morgan Stanley given on Thursday, September 1. On Monday, October 19 the stock rating was upgraded by Jyske Bank to “Strong Buy”. BNP Paribas upgraded Novo Nordisk A S (ADR) (NYSE:NVO) on Tuesday, September 13 to “Outperform” rating. HSBC upgraded Novo Nordisk A S (ADR) (NYSE:NVO) on Wednesday, August 31 to “Hold” rating. The firm has “Market Perform” rating by Leerink Swann given on Friday, August 28. The rating was initiated by Piper Jaffray on Friday, September 23 with “Neutral”. The company was upgraded on Friday, August 28 by Zacks. UBS downgraded the shares of NVO in a report on Monday, February 8 to “Sell” rating. The rating was downgraded by JP Morgan on Friday, September 9 to “Neutral”.
According to Zacks Investment Research, “Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world’s largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.”
More notable recent Novo Nordisk A S (ADR) (NYSE:NVO) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on February 11, 2011, also Marketwatch.com with their article: “Plus the latest data from Realtor.com on 21 home markets across the US” published on July 03, 2009, Businessfinancenews.com published: “Novo Nordisk Earnings Preview: What to Expect” on August 02, 2016. More interesting news about Novo Nordisk A S (ADR) (NYSE:NVO) were released by: Businessfinancenews.com and their article: “Novo Nordisk A/S (ADR): Diabetic Leader Gets Yet Another FDA Approval” published on May 26, 2016 as well as Investorplace.com‘s news article titled: “Why American Airlines Group Inc (AAL), Novo Nordisk A/S (ADR) (NVO) and …” with publication date: June 14, 2016.
NVO Company Profile
Novo Nordisk A/S, incorporated on November 28, 1931, is a healthcare company. The Firm is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business divisions include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.